These effects are consistent with the vasodilatory effects of PDE5-inhibitors and are probably due to increased cGMP levels in vascular smooth muscle cells.
Need toimed on kooskõlas PDE5- inhibiitorite veresooni laiendava toimega ning on arvatavasti tingitud cGMP taseme tõusust veresoonte silelihasrakkudes.